PTO/SB/26 (10-07)

Approved for use through 10/31/2007. OMB 0651-0331

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to a collection of information unless it displays a valid OMB control number.

Chac, the Paperwork	(Neduction Act of 1886, the persons are required to respond to a conscitution of minormation of	account a oping our raise Office control fluribon.
TERMINAL	DISCLAIMER TO OBVIATE A DOUBLE PATENTING REJECTION OVER A "PRIOR" PATENT	Docket Number (Optional) 112300-1542
In re Application of: Anthony J. Baerlocher		
Application No.: 10/662,929		
Filed: September 15, 20	003	
For: GAMING DEVICE HAVING RELATED MULTI-GAME BONUS SCHEME		
The owner*, <u>IGT</u> except as provided below, the terminal part of the statutory term of any patent granted on the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term prior patent No. <u>6.834.93</u> as the sterm of said prior patent in 50 sizes. 154 and 173, and as the term of said prior patent is presently shortened by any terminal disclaimer. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the prior patent are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.		
In making the above disclaimer, the owner does not disclaim the terminal part of the term of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 50 LS. C. 154 and 173 of the prior patent, "as the term of said prior patent is presently shortened by any terminal disclaimer," in the event that said prior patent later: expires for failure to pay a maintenance fee; is held unenforceable; is found invalid by a count of competent jurisdiction; is statutority disclaimed in whole or terminally disclaimed under 37 CFR 1.321; has all claims canceled by a reexamination certificate; is reviseued; or execution that terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.		
Check either box 1 or 2 below, if appropriate.		
 For submissions on behalf of a business/organization (e.g., corporation, partnership, university, government agency, etc.), the undersigned is empowered to act on behalf of the business/organization. 		
I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.		
2. The undersigned is an attorney or agent of record. Reg. No. 35,602		
	along House:	
		October 23, 2007
	Signature	Date
Adam H. Masia		
Typed or printed name		
		312-807-4284 Telephone Number
✓ Terminal disclaimer fee under 37 CFR 1.20(d) included.		
WARNING: Information on this form may become public, Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.		
*Statement: under 37 CFR 3.73(b) is required if terminal disclaimer is signed by the assignee (owner). Form PTO/SB/96 may be used for making this certification. See MPEP § 324.		
This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is proved by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete.		

to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 111 and 1.14. This collection is estimated to take 72 immufates to completed application from the USPTC. Three wile welly explored growth in Edwards application from the USPTC. Three wile welly explored growth in Edwards and Confidential applications and the USPTC and US